

1    **Title:**            **Anti-inflammatory effects and molecular mechanisms of 8-prenyl**  
2                        **quercetin**

3  
4    **Authors:**        Ayami Hisanaga<sup>a</sup>, Rie Mukai<sup>b</sup>, Kozue Sakao<sup>a, c</sup>, Junji Terao<sup>b</sup>, De-Xing  
5                        Hou <sup>a, c, ¶</sup>

6    **Affiliations:**   <sup>a</sup>United Graduate School of Agricultural Science, Kagoshima University,  
7                        Kagoshima, Japan. <sup>b</sup>Department of Food Science, Institute of Health  
8                        Biosciences, University of Tokushima Graduate School, Tokushima,  
9                        Japan. <sup>c</sup>Faculty of Agriculture, Kagoshima University, Kagoshima,  
10                      Japan.

11  
12    <sup>¶</sup>**Corresponding author:** Professor De-Xing Hou, Faculty of Agriculture, Kagoshima University,  
13    Korimoto 1-21-24, Kagoshima, 890-0065, Japan.

14    E-mail: hou@chem.agri.kagoshima-u.ac.jp (D.-X Hou), Fax/Tel: +81 99 285 8649

15  
16    *Abbreviations:*

17    COX-2, cyclooxygenase-2; ERK, extracellular signal-regulated kinase; FBS, fetal  
18    bovine serum; FITC, fluorescein isothiocyanate; G-CSF, granulocyte  
19    colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating  
20    factor; IFN- $\gamma$ , interferon-gamma; IL-1 $\alpha$  (3, 6, 9, 13, 17), interleukin-1 alpha (3, 6, 9, 13,  
21    17); iNOS, inducible nitric oxide synthase; *i.p.*, intraperitoneally; JNK, Jun-*N*-terminal  
22    kinase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MCP-1,  
23    monocyte chemotactic protein-1; MEK, MAPK/ERK kinase; NO, nitric oxide; NF- $\kappa$ B,  
24    nuclear factor-kappa B; PGE<sub>2</sub> , prostaglandin E<sub>2</sub>; PQ, 8-prenyl quercetin; Q, quercetin;  
25    SAPK, stress-activated protein kinase; SEK, SAPK/Erk kinase (MKK4); *s.c.*,  
26    subcutaneously; TLR4, Toll-like receptor 4; TNF- $\alpha$ , tumor necrosis factor alpha.

27

28 **Scope:** 8-prenyl quercetin (PQ) is a typical prenylflavonoid distributed in plant foods  
29 and shows higher potential bioactivity than its parent quercetin (Q) although the  
30 mechanisms are not fully understood. This study aims to clarify the anti-inflammatory  
31 effects and molecular mechanisms of PQ in cell and animal models, compared to Q.

32 **Methods and results:** RAW264.7 cells were treated with PQ or Q to investigate the  
33 influence on the production of inducible nitric oxide synthase (iNOS),  
34 cyclooxygenase-2 (COX-2) and protein kinases by Western blotting. Nitric oxide (NO)  
35 and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) were measured by the Griess method and ELISA,  
36 respectively. Cytokines were assayed by the multiplex technology. Mouse paw edema  
37 was induced by lipopolysaccharide (LPS). The results revealed that PQ had stronger  
38 inhibition on the productions of iNOS, COX-2, NO, PGE<sub>2</sub>, and 12 kinds of cytokines,  
39 than Q. PQ also showed *in vivo* anti-inflammatory effect by attenuating mouse paw  
40 edema. Molecular data revealed that PQ had no competitive binding to Toll-like  
41 receptor 4 (TLR4) with LPS, but directly targeted SEK1-JNK1/2 and MEK1-ERK1/2.

42 **Conclusion:** PQ as a potential inhibitor revealed anti-inflammatory effect in both cell  
43 and animal models at least by targeting SEK1-JNK1/2 and MEK1-ERK1/2.

44

45 **Keywords:** Prenyl quercetin / Inflammatory mediators / Cellular signaling / Direct  
46 binding / Molecular targets

47

## 48 **1 Introduction**

49 Prenylflavonoids are naturally occurring flavonoids possessing a C5 isoprenoid unit in a  
50 diphenylpropane structure. The roots, leaves and seeds of *Moraceae*, *Leguminosae* and  
51 *Asteraceae* are major sources of prenylflavonoids although more than 1000

52 prenylflavonoids have been found in the plants [1, 2]. In recent years, their potential  
53 benefits for human health have been considered because prenylflavonoids are reported  
54 to have antibacterial, antioxidant and estrogenic activities [3]. It is noticed that  
55 prenylation of flavonoids could enhance their biological functions and bioavailability.  
56 For example, prenylation of naringenin and genistein enhanced their estrogenicity [4].  
57 Prenylated naringenin also enhanced the accumulation of naringenin in muscle tissue,  
58 resulting in the prevention of muscle atrophy in rodent model [5]. Thus, molecular  
59 mechanisms of prenylflavonoids should be taken into account to estimate the biological  
60 functions.

61 Quercetin (Q) is a representative compound of naturally occurring flavonoid present in  
62 many vegetables and fruits [6]. Extensive data have indicated that Q has many  
63 biological functions [7, 8, 9]. Recent studies have demonstrated that Q has  
64 anti-inflammatory effects in both mouse macrophage cell [10] and rat models [11].  
65 Moreover, 8-prenyl quercetin (PQ) is found in *Desmodium caudatum* [12] that is a  
66 traditional herb used for anti-inflammation in Japan [13]. Thus, we challenge to clarify  
67 the effect and molecular mechanisms of anti-inflammation by PQ, compared to its  
68 parent Q.

69 During inflammatory disease, the primary cells of chronic inflammation are  
70 macrophages that produce excess amounts of mediators such as nitric oxide (NO),  
71 prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), and pro-inflammatory cytokines [14], which play pivotal roles  
72 in consequences of inflammation [15]. Although the cellular signaling pathways  
73 regulating the inflammation are very complicated, mitogen-activated protein kinase  
74 (MAPK) and nuclear factor-kappa B (NF-κB) pathways have been suggested to be key  
75 pathways for the regulations of inflammatory mediator expressions [14]. MAPK can  
76 stimulate the production of inflammatory mediators such as inducible nitric oxide

77 synthase (iNOS), cyclooxygenase-2 (COX-2) and cytokines in bacterial  
78 lipopolysaccharide (LPS)-activated macrophages [16, 17, 18]. Moreover, recent several  
79 lines of studies have showed that polyphenolic compounds could directly bind to  
80 MAPK proteins to attenuate the kinase signaling. For example, myricetin [19],  
81 procyanidin B2 [20] could directly bind to MAPK/ERK kinase (MEK) to suppress  
82 MEK phosphorylation and downstream signaling.

83 Based on the properties of prenylflavonoids and the information of inflammation  
84 processes, we investigated the anti-inflammatory effects and molecular mechanisms of  
85 PQ, compared to Q. First of all, we used mouse macrophage-like cells (RAW264.7),  
86 which can be stimulated with LPS to mimic a status of infection and inflammation, to  
87 screen the influence of PQ on the productions of iNOS, NO, COX-2, PGE<sub>2</sub>, and  
88 cytokines. Then, we confirmed the *in vivo* anti-inflammatory effects of PQ using a  
89 mouse paw edema model. Finally, we investigated the modulation of PQ on  
90 LPS-induced inflammatory signaling pathway, and challenged to clarify the molecular  
91 targets of PQ by chemical biology approaches.

92

## 93 **2 Materials and methods**

### 94 **2.1 Materials**

95 PQ (Fig. 1A) was synthesized as described previously [21]. Q (Fig. 1B) was purchased  
96 from Sigma (St. Louis, MO, USA). PQ and Q were dissolved in DMSO (0.2% final  
97 concentration in cultural medium). LPS and fluorescein isothiocyanate (FITC)  
98 conjugated-LPS (*Escherichia coli* Serotype 055:B5) were from Sigma (St. Louis, MO,  
99 USA). The antibodies against iNOS, COX-2, MEK1,  $\alpha$ -tubulin and anti-goat IgG-HRP  
100 were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The other antibodies  
101 were from Cell Signaling Technology (Beverly, MA, USA). CNBr-activated Sepharose

102 4B was from GE Healthcare.

103

## 104 **2.2 Cell culture**

105 RAW264.7 cells were purchased from the American Type Culture Collection (Manassas,  
106 VA, USA) and cultured in Dulbecco's modified Eagle's medium containing 10% fetal  
107 bovine serum (FBS), 4 mM *L*-glutamine, and 2 mM Penicillin-Streptomycin Mixed  
108 Solution. After pre-culture for 24 h, the cells were starved in serum-free medium to  
109 eliminate the influence of FBS. The cells were then treated for 30 min with PQ or Q or  
110 DMSO as control vehicle (0.2% final concentration of DMSO in cultural medium)  
111 before exposure to 40 ng/mL LPS for the indicated times in each experiment.

112

## 113 **2.3 Measurement of nitrite and PGE<sub>2</sub>**

114 Nitrite was measured to estimate NO production with the Griess method [22]. In brief,  
115 RAW264.7 macrophage cells ( $1 \times 10^6$  cells/dish) were seeded into 6-cm dish. The cells  
116 culture and treatments were described in Section 2.2, and the culture medium from each  
117 dish was collected after LPS treatment for 12 h. The nitrite concentration in the culture  
118 medium was detected by the reaction with the Griess reagent for 10 min at room  
119 temperature, and the absorbance was measured at 550 nm wavelength.

120 PGE<sub>2</sub> in cultural medium was measured with a PGE<sub>2</sub> enzyme immunoassay kit  
121 (Cayman Co., St. Louis, MO) according to manufacturer's manual [23]. In brief,  
122 RAW264.7 cells ( $1.2 \times 10^5$  cells/well) were seeded into each well of 12-well plates. The  
123 cells culture and treatments were described in Section 2.2, and the culture medium from  
124 each well was collected after LPS treatment for 12 h. The level of PGE<sub>2</sub> released into  
125 culture medium was determined by measuring absorbance at 405 nm in a microplate  
126 reader.

127

## 128 **2.4 Cytokine determination by the multiplex technology**

129 The method has been described in our previous report [24]. In brief, RAW264.7 cells  
130 ( $1.2 \times 10^5$  cells/well) were seeded into each well of 12-well plate. The cells culture and  
131 treatments were described in Section 2.2, and the culture medium from each well was  
132 collected after LPS treatment for 12 h. The levels of cytokines in culture medium was  
133 measured with Bio-Plex Pro Mouse Cytokine 23-Plex Panel kit (Bio-Rad Laboratories)  
134 including IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40),  
135 IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN- $\gamma$ , KC, MCP-1, MIP-1 $\alpha$ ,  
136 MIP-1 $\beta$ , RANTES and TNF- $\alpha$ . The assay was performed with a Bio-Plex machine  
137 (Bio-Plex 200 System, Bio-Rad) according to the manufacturer's instructions, and the  
138 data were analyzed with the Bio-Plex manager software (version 5.0).

139

## 140 **2.5 Western blotting**

141 Western blotting was performed as described previously [22]. In brief, RAW264.7 cells  
142 ( $1 \times 10^6$  cells/dish) were seeded into each 6-cm dish. The cell culture and treatments  
143 were described in Section 2.2. The cells were lysed in a lysis buffer, and boiled for 5  
144 min. Approximately 20-60  $\mu$ g of proteins were run on 10% SDS-PAGE and then  
145 transferred to PVDF membrane (GE Healthcare, UK). The blotted membrane was  
146 incubated with specific primary antibody overnight at 4 °C and further incubated for 1 h  
147 with HRP-conjugated secondary antibody. Bound antibodies were detected by ECL  
148 agent and further quantified by Lumi Vision Imager software (TAITEC Co., Japan).

149

## 150 **2.6 *In vivo* paw edema model**

151 The animal experiments were conducted in accordance with the guidelines of the

152 Animal Care and Use Committee of Kagoshima University (Permission N0. A12005).  
153 Male ICR mice (4 weeks old) from Japan SLC Inc were group-housed under controlled  
154 light (12 h light/day) and temperature (25 °C). All the animals had free access to water  
155 and feed in a home cage. The mice were randomly divided into four groups: control,  
156 LPS, LPS plus PQ or Q. PQ or Q was dissolved in PBS containing 2% DMSO and  
157 administered to the mice in 1 µM/kg for PQ or 2 µM/kg for Q by intraperitoneal (*i.p.*)  
158 injection for 4 days. LPS were then injected subcutaneously (*s.c.*) to paw in a dose of 1  
159 mg/kg. Paw thickness was measured using caliper (model 19975, Shinwa Rules Co.  
160 Ltd) before and every hour after LPS treatment until 3 h. After 3 h, mice were sacrificed  
161 and blood serums were collected from heart. The serums without any dilution were used  
162 to detect IL-6 by mouse ELISA Ready-SET-Go kit (eBioscience) according to  
163 manufacturer's instructions.

164

## 165 **2.7 Flow cytometric assay**

166 The competition assay of PQ and LPS for Toll-like receptor 4 (TLR4) was performed by  
167 flow cytometry using the FITC-conjugated LPS [25]. RAW264.7 cells ( $5 \times 10^5$  cells/ml  
168 in serum-free medium) were treated with or without PQ (15 µM) or cold-LPS (non  
169 FITC-conjugated LPS) (100 ng/ml) for 30 min before expose to FITC-LPS (10 ng/ml)  
170 for 30 min. After washing, the fluorescence emitted was analyzed at FL1 (530 nm) with  
171 flow cytometer (CyFlow, Partec).

172

## 173 **2.8 Molecular modeling**

174 Computer modeling was performed as described previously [26]. The modeling of PQ  
175 or Q to TLR4 (PDB ID: 3FXI) [27, 28], SEK1 (PDB ID: 2DYL) [29], JNK1 (PDB ID:  
176 3PZE), MEK1 (PDB ID: 1S9J) [29], and ERK2 (PDB ID: 2Y9Q) was performed using

177 Molecular Operating Environment TM software (MOE, Version 2012.10, Chemical  
178 Computing Group Inc.). Hydrogen atoms were first added, and force field (MMFF94x)  
179 atomic charges were assigned. Docking of PQ or Q to protein was done using  
180 MOE-ASEDock 2013 software [30].

181

## 182 **2.9 *Ex vivo* pull-down assay**

183 *Ex vivo* pull-down assay was performed as described in our previous paper [26].  
184 Briefly, PQ and Q (5  $\mu$ M) were coupled to CNBr-activated Sepharose 4B beads (25 mg)  
185 in a coupling buffer [0.5 M NaCl, 0.1 M NaHCO<sub>3</sub> (pH 8.3) and 25 % DMSO] for  
186 overnight at 4 °C according to the manufacturer's instructions. The mixture was washed  
187 with 5 volumes of coupling buffer and then resuspended by 5 volumes of 0.1 M  
188 Tris-HCl buffer (pH 8.0) for 2 h rotation at room temperature (RT) to block any  
189 remaining active groups. After washing three cycles with acetate buffer [0.1 M acetic  
190 acid (pH 4.0) and 0.5 M NaCl], the conjugated beads were further washed by wash  
191 buffer [0.1 M Tris-HCl (pH 8.0) and 0.5 M NaCl]. The RAW264.7 cell lysates (500  
192  $\mu$ g/ml) were then incubated overnight at 4 °C with Sepharose 4B beads, PQ- or  
193 Q-conjugated Sepharose 4B beads (100  $\mu$ l, 50% slurry) in a reaction buffer [50 mM  
194 Tris-HCl (pH 8.5), 5 mM EDTA, 150 mM NaCl, 1mM DTT, 0.01% Nonidet P-40, 2  
195  $\mu$ g/ml BSA, 0.02 mM PMSF and 1  $\mu$ g protease inhibitor cocktail]. The beads were  
196 washed 5 times with 50 mM Tris-HCl (pH 7.5) containing 5 mM EDTA, 200 mM NaCl,  
197 1 mM DTT, 0.02% Nonidet P-40 and 0.02 mM PMSF. The proteins bound to the beads  
198 were detected by Western blotting with each specific antibody.

199

## 200 **2.10 Statistical analysis**

201 The difference between treated and control cells were analyzed by analysis of variance



202 tests or Tukey's test. A probability of  $p < 0.05$  was considered significant.

203

### 204 **3 Results**

#### 205 **3.1 The inhibitory effects of PQ and Q on the production of inflammatory factors**

206 To investigate the effect of PQ and Q on the production of inflammatory factors, we  
207 first used LPS-activated RAW264.7 cells [14]. As shown in Fig. 2A and 2B, the  
208 productions of LPS-induced iNOS and COX-2 protein were significantly suppressed by  
209 PQ and Q in dose-dependent manner. PQ almost completely suppressed the productions  
210 at 15  $\mu\text{M}$  while Q slightly did even at 30  $\mu\text{M}$ . PQ had two-fold stronger inhibition than  
211 Q. Since iNOS and COX-2 are the enzymes to synthesize NO and PGE<sub>2</sub>, respectively,  
212 we next examined the effects of PQ and Q on the productions of NO and PGE<sub>2</sub> in such  
213 treatment. A parallel inhibitory effects by PQ and Q were observed in LPS-induced  
214 nitrite (Fig. 2C and 2D) and PGE<sub>2</sub> (Fig. 2E and 2F) production. These results indicated  
215 that the effective dose for the inhibition is 15  $\mu\text{M}$  for PQ or 30  $\mu\text{M}$  for Q, thus, we used  
216 15  $\mu\text{M}$  PQ and 30  $\mu\text{M}$  Q for the following cell experiments.

217 We further examined the levels of 23 kinds of cytokines in the culture medium of  
218 treated cells as described in Section 2. LPS treatment for 12 h enhanced more than  
219 five-fold level of G-CSF, TNF- $\alpha$ , RANTES, IL-6, MCP-1, GM-CSF, more than  
220 two-fold level of IL-12 (p70), KC, MIP-1 $\beta$ , IL-1 $\alpha$ , IL-10, IL-9; and less than two-fold  
221 in IL-13, IL-1 $\beta$ , IL-4, IL-17, IL-3, IFN- $\gamma$ , IL-12 (p40), Eotaxin, IL-5, MIP-1 $\alpha$ , IL-2,  
222 compared to that of the cells without LPS treatment [24]. Pretreatment with PQ or Q at  
223 the indicated concentrations decreased significantly the level of IL-1 $\alpha$ , IL-6, IFN- $\gamma$ ,  
224 TNF- $\alpha$ , IL-3, IL-9, IL-13, GM-CSF, Eotaxin, IL-17, G-CSF, and MCP-1 (Fig. 3), but  
225 did not affect significantly other 11 kinds of cytokines (data not shown). PQ also had  
226 stronger inhibition for these pro-inflammatory cytokines than Q.

227

### 228 **3.2 Inhibition of LPS-induced paw edema in mice**

229 To confirm the anti-inflammatory effects of PQ and Q *in vivo*, we used the model of  
230 mouse paw edema induced by LPS (Fig. 4A) as described previously [24]. The results  
231 showed that LPS treatment increased significantly the paw thickness with maximum  
232 after 1 h and following down after 2 h. Pretreatment with 1  $\mu$ M/kg PQ or 2  $\mu$ M/kg Q for 4  
233 days reduced significantly LPS-induced paw thickness during this period, compared  
234 with LPS treatment alone. As controls, treatment with PBS or PQ or Q only in 2 %  
235 DMSO did not show any effect on paw edema (Fig. 4B). Simultaneously, we checked  
236 the serum level of pro-inflammatory IL-6 by ELISA. As shown in Fig. 4C, pretreatment  
237 with 1  $\mu$ M/kg PQ or 2  $\mu$ M/kg Q decreased significantly the level of LPS-induced IL-6.  
238 These data confirmed the anti-inflammatory effect of PQ or Q *in vivo*.

239

### 240 **3.3 The effect of PQ and Q on the binding of LPS to TLR4.**

241 TLR4 is a specific receptor for LPS to initiate the inflammatory responses. Our data  
242 showed that the productions of LPS-induced inflammatory mediators were suppressed  
243 by PQ and Q in both cell and mouse models. We wonder whether PQ or Q binds to  
244 TLR4 competitively with LPS to block LPS-induced inflammation. Therefore, we first  
245 performed computational analysis based on the structure of TLR4-MD2 complex (PDB  
246 ID: 3FXI) and PQ or Q. As shown in Fig. 5A, both PQ and Q docked in the most same  
247 region of TLR4-MD2 complex with three hydrogen bonds for PQ, and with four  
248 hydrogen bonds for Q. The PQ or Q binding region is different with LPS binding region,  
249 suggesting that PQ and Q may have no competition binding to TLR4-MD2 complex  
250 with LPS. To confirm this, we further used FITC-conjugated LPS to investigate whether  
251 PQ or Q binds to TLR4 competitively with LPS by flow cytometric assay (see Section

252 2). As shown left panel in Fig. 5B, treatment with FITC-conjugated LPS produced a  
253 strongest peak of fluorescence that could be suppressed by adding 10-fold of cold-LPS,  
254 suggesting the FITC-conjugated LPS worked in this cell system. Next, we added PQ or  
255 Q in this assay system. As shown right panel in Fig. 5B, PQ addition did not reduce the  
256 fluorescent strength. These data further support that PQ and Q may have no competitive  
257 binding to TLR4-MD2 complex with LPS although PQ or Q itself shows fluorescence  
258 in this wavelength. Thus, these data suggest that PQ or Q might exert anti-inflammatory  
259 action by targeting cytoplasmic protein kinases.

260

### 261 **3.4 Modulation of PQ and Q on MAPK signaling**

262 Our data revealed that the inhibition of PQ or Q on inflammatory factors is not due to its  
263 competitive binding to TLR4. It is recently noticed that PQ or Q can efflux the cells [31,  
264 32] and modulate MAPK signaling to regulate pro-inflammatory mediators. Thus, we  
265 investigated the effects of PQ and Q on the LPS-induced phosphorylation of MAPK in  
266 RAW264.7 cells. The cells were treated with 15  $\mu$ M PQ or 30  $\mu$ M Q for 30 min before  
267 exposure to 40 ng/ml LPS for 30 min. As shown in Fig. 6, PQ suppressed markedly  
268 phosphorylation of SEK1-JNK1/2 and MEK1-ERK1/2 signaling while Q only slightly  
269 suppressed them. Both PQ and Q did not suppress the phosphorylation of MKK3/6-p38  
270 (data not shown).

271

### 272 **3.5 Binding ability of PQ and Q to SEK1-JNK1/2 and MEK1-ERK1/2**

273 Our data suggest that SEK1-JNK1/2 and MEK1-ERK1/2 are potential targets for PQ  
274 and Q to inhibit inflammatory signaling. Thus, we investigated whether the PQ and Q  
275 bind to each protein kinase directly, using bead-bound pulldown assay which has been  
276 validated as effective screening tool in our previous study [26]. PQ or Q is coupled with

277 CNBr-sepharose 4B beads, and then incubated with protein lysate extracted from  
278 RAW264.7 cells. Bound protein kinase was detected by Western blotting with antibody  
279 after washing out. As shown in Fig. 7A, SEK1 and JNK1/2 were detected in the  
280 Sepharose 4B beads coupled with PQ (54.2% and 31.6% binding rate) and with Q  
281 (31.6% and 12.6% binding rate), but was not detected in the Sepharose 4B beads alone.  
282 As the same fashion, MEK1 and ERK1/2 were detected in the Sepharose 4B beads  
283 coupled with PQ (75.6% and 77.3% binding rate), and with Q (21.2% and 37.1 %  
284 binding rate), but was not detected in the Sepharose 4B beads alone (As shown in Fig.  
285 7B). These data showed that PQ and Q could bind directly to SEK1, JNK1/2, MEK1  
286 and ERK1/2. Moreover, PQ had stronger binding activity to these protein kinases than  
287 Q.

288

### 289 **3.6 Docking model between PQ/Q and SEK1-MEK1 kinases**

290 To know how PQ or Q binds to SEK1 and MEK1 kinases, we performed computer  
291 modeling of PQ or Q bound to these protein kinases, using the software as described in  
292 Section 2. The results provided the interesting information that three hydrogen bonds  
293 were formed between PQ and Glu175 and Asp259 residues of MKK4 (SEK1), which  
294 configured nearby ATP-binding pocket in left panel, and four hydrogen bonds were  
295 formed between Q and Glu175, Asp259, and Asp277 residues of MKK4 (SEK1), which  
296 configured a part of ATP-binding pocket in right panel. The domains for PQ and Q  
297 binding are very close, almost the same. As shown in Fig. 8B, two hydrogen bonds were  
298 formed between PQ and Lys55 and Asp151 residues of JNK1, which configured a part  
299 of ATP-binding pocket in right panel, and three hydrogen bonds were formed between  
300 Q and Val80, Glu109, and Lys166 residues of JNK1, which configured a part of  
301 ATP-binding pocket in left panel. The domains for PQ and Q binding are in different

302 domains. Three hydrogen bonds were formed between PQ and Arg181, Glu182 and  
303 Asp351 residues of MEK1 (Fig.8C), which configured a part of MEK1 catalytic domain  
304 in right panel. Two hydrogen bonds were formed between Q and Asp365 of MEK1,  
305 which configured a part of MEK1 catalytic domain in left panel. The domains of MEK1  
306 for PQ and Q binding are different (Fig.8C). Four hydrogen bonds were formed  
307 between PQ and Asp251, Lys272 and Asp291 residues of ERK2 (Fig. 8D), which  
308 configured a part of ERK2 catalytic domain in left panel, and four hydrogen bonds were  
309 formed between Q and MEK1, same as PQ in left panel. These docking results support  
310 our pull-down binding data between PQ or Q and SEK1-MEK1 kinases.

311

#### 312 **4 Discussion**

313 In the present study, we investigated the anti-inflammatory effects and molecular  
314 mechanisms of 8-prenyl quercetin, compared to its parent quercetin, in both cell and  
315 animal models. In the cell model, we demonstrated that PQ had more than two-fold  
316 stronger inhibition on LPS-induced productions of pro-inflammatory factors (iNOS, NO,  
317 COX-2, PGE<sub>2</sub>) and cytokines (IL-1 $\alpha$ , IL-6, IFN- $\gamma$ , TNF- $\alpha$ , IL-3, IL-9, IL-13, GM-CSF,  
318 Eotaxin, IL-17, G-CSF, and MCP-1, IL-12 (p70), TNF- $\alpha$ , and MCP-1). In the animal  
319 model, we observed that PQ also showed more than two-fold stronger inhibition on  
320 mouse paw edema (Fig. 4). Thus, our data suggested that PQ is more potential inhibitor  
321 for LPS-induced inflammation than its parent form.

322 The issues concerned are the molecular mechanisms that how PQ suppressed  
323 LPS-induced inflammation. TLR4 is an important sensor for LPS by enhancing the  
324 binding of LPS to MD-2 to form LPS-TLR4-MD2 complex to trigger signaling  
325 cascades that involve activation of MAPK, NF- $\kappa$ B, and anti-inflammatory mediators

326 [33]. We wonder whether PQ and Q compete with LPS for binding to TLR4. To clarify  
327 this, we first performed computational docking analysis based on the structure of  
328 TLR4-MD2 complex (PDB ID: 3FXI) and PQ or Q. The data showed that both PQ and  
329 Q docked in the different domain of TLR4-MD2 complex with LPS, suggesting that PQ  
330 and Q might have no competitive binding to TLR4-MD2 complex with LPS. To confirm  
331 this, we further used FITC-conjugated LPS to investigate whether PQ or Q has  
332 competitive binding with TLR4 by flow cytometric assay. Our data showed that both  
333 PQ and Q did not reduce the fluorescent strength by FITC-conjugated LPS, further  
334 supporting that PQ and Q might have no competitive binding to TLR4-MD2 complex  
335 with LPS. These data suggest that PQ and Q might attenuate cellular inflammatory  
336 signaling by inhibiting the activation of cellular protein kinases.

337 MAPK signaling is one of the important cell signaling pathways that regulate  
338 cytokines and pro-inflammatory mediators such as IL-1, IL-6, TNF- $\alpha$ , and iNOS during  
339 inflammatory response although the cellular signaling pathways regulating  
340 inflammation are very complicated. We first investigated the potential of PQ and Q  
341 binding to MAP kinases by the bead-bound pulldown assay, which has been validated  
342 as an effective screening tool in our previous study [26]. SEK1-JNK1/2 and  
343 MEK1-ERK1/2 were detected in the Sepharose 4B beads coupled with PQ and cellular  
344 lysate, but not found in Sepharose 4B beads alone (Fig. 7). These data supported that  
345 PQ might target the signaling molecules of SEK1-JNK1/2 and MEK1-ERK1/2 by direct  
346 binding. Furthermore, we performed computer modeling of PQ and Q bound to  
347 SEK1-JNK1/2 and MEK1-ERK1/2, using the software of three dimensional  
348 pharmacophore modeling for the interaction of a small molecule with protein. The  
349 results provided the interesting information that several hydrogen bonds were found  
350 between the hydroxyl groups of PQ or Q and amino acid residues of SEK1-JNK1/2 and

351 MEK1-ERK1/2 (Fig. 8A- 8D).

352 Moreover, the docking domain by PQ or Q is not completely located in the  
353 ATP-binding pocket of these protein kinases, but configured nearby or a part of  
354 ATP-binding pocket. These data at least suggest that PQ or Q may dock these domains  
355 to modulate the 3D-structure of these protein kinases to influence the phosphorylation,  
356 rather than competing with ATP. Our data indicate that the downregulation of  
357 SEK1-JNK1/2 and MEK1-ERK1/2 pathways by PQ or Q is at least involved in the  
358 inhibition of LPS-induced inflammation.

359 On the other hand, direct binding efficiency for PQ is 2-3 fold higher than that for Q  
360 although the binding domains of these protein kinases for PQ and Q were very close,  
361 almost the same. The reason may be related to the efficiency of cellular uptake and  
362 bioaccumulation. It is reported that prenylation increased the hydrophobicity and  
363 affinity of Q to hydrophobic phospholipid bilayer membranes [31], which might  
364 enhance the cellular uptake of flavonoids and result in their biological activities in *in*  
365 *vitro* model systems [3]. *In vivo* data confirmed that prenylation enhances accumulation  
366 of naringenin in mouse muscle tissue after long-term feeding, and accumulation of  
367 quercetin in liver tissue [5]. Therefore, our data could support that the higher direct  
368 binding efficiency for PQ may be due to its efficiency in cellular uptake and  
369 bioaccumulation enhanced by prenylation.

370 In summary, we demonstrated that 8-prenyl quercetin has stronger anti-inflammatory  
371 activity than its parent form *in vitro* and *in vivo*. Moreover, the downregulation of  
372 MAPK signaling pathways is at least involved in the inhibition of inflammatory  
373 mediators by PQ. Direct binding assay and molecule docking analysis revealed that  
374 SEK1-JNK1/2 and MEK1-ERK1/2 might be direct molecule targets for PQ. These  
375 results from cell and mouse models provide a comprehensive data for understanding the

376 anti-inflammatory effects and molecular mechanisms of PQ.

377

### 378 **Acknowledgments**

379 This work was partly supported by the fund of Scholar Research of Kagoshima  
380 University, and by the Program for Promotion of Basic and Applied Researches for  
381 Innovations in Bio-oriented Industry in Japan.

382

### 383 **5 References**

- 384 [1] Yazaki, K., Sasaki, K., Tsurumaru, Y., Prenylation of aromatic compounds, a key  
385 diversification of plant secondary metabolites. *Phytochemistry*, 2009, 70,  
386 1739-1745.
- 387 [2] Barron, D., Ibrahim, R. K., Isoprenylated flavonoids-A survey, *Phytochemistry*,  
388 1996, 43, 921-982.
- 389 [3] Chen, X., Mukwaya, E., Wong, M. S., et al., A systematic review on biological  
390 activities of prenylated flavonoids. *Pharm. Biol.* 2014, 52, 655-660
- 391 [4] Kretzschmar, G., Zierau, O., Wober, J., et al., Prenylation has a compound specific  
392 effect on the estrogenicity of naringenin and genistein. *J. Steroid Biochem. Mol.*  
393 *Biol.* 2010, 118, 1-6
- 394 [5] Mukai, R., Horikawa, H., Fujikura, Y., et al., Prevention of disuse muscle atrophy  
395 by dietary ingestion of 8-prenylnaringenin in denervated mice. *PLoS ONE*. 2012, 7,  
396 e45048.
- 397 [6] Peterson, J., Dwyer, J., Flavonoids: Dietary occurrence and biochemical activity.  
398 *Nutr. Res.* 1998, 18, 1995-2018.
- 399 [7] Moskaug, J.O., Carlsen, H., Myhrstad, M., et al., Molecular imaging of the  
400 biological effects of quercetin and quercetin-rich foods. *Mech. Ageing Dev.* 2004,



- 401 125, 315-324.
- 402 [8] Tanigawa, S., Fujii, M., Hou, D. X., Stabilization of p53 is involved in  
403 quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. *Biocsci.*  
404 *Biotechnol. Biochem.* 2008, 72, 797-804.
- 405 [9] Formica, J. V. and Regelson, W., Review of biology of quercetin and related  
406 bioflavonoids. *Fd Chem. Toxic.* 1995, 33, 1061-1080.
- 407 [10] Cho, S. Y., Park, S. J., Kwon, M. J., et al., Quercetin suppresses proinflammatory  
408 cytokines production through MAP kinases and NF- $\kappa$ B pathway in  
409 lipopolysaccharide-stimulated macrophage. *Mol. Cell. Biochem.* 2003, 243,  
410 153-160.
- 411 [11] Comalada, M., Camesco, D., Sierra, S., et al., In vivo quercetin anti-inflammatory  
412 effect involves release of quercetin, which inhibits inflammation through  
413 down-regulation of the NF- $\kappa$ B pathway. *Eur. J. Immunol.* 2005, 35, 584-592.
- 414 [12] Wu, Y., Luo, Q., Sun, C., et al., [Chemical constituents contained in *Desmodium*  
415 *caudatum*]. *Zhongguo Zhong Yao Za Zhi.* 2012, 37, 1788-1792.
- 416 [13] Sasaki, H., Kashiwada, Y., Shibata, H., et al., Prenylated flavonoids from the roots  
417 of *Desmodium caudatum* and evaluation of their antifungal activity. *Planta Med.*  
418 2012, 78, 1851-1856.
- 419 [14] Laskin, D. L., Laskin, J. D., Role of macrophages and inflammatory mediators in  
420 chemically induced toxicity, *Toxicology*, 2001, 160, 111-118.
- 421 [15] Hadad, J. J., Cytokines and related receptor-mediated signaling pathways,  
422 *Biochem. Biophys. Res. Commun.* 2002, 297, 700-713.
- 423 [16] Lu, Y. C., Yeh, W. C., Ohashi, P. S., LPS/TLR4 signal transduction pathway,  
424 *Cytokine*, 2008, 42, 145-151.
- 425 [17] Chang, L., Karin, M., Mammalian MAP kinase signalling cascades, *Nature*, 2001,

426 410, 37-40.

427 [18] Rossol, M., Heine, H., Meusch, U., et al., LPS-induced cytokine production in  
428 human monocytes and macrophages. *Crit. Rev. Immunol.* 2011, *31*, 379-446.

429 [19] Lee, K. W., Kang, N. J., Rogozin, E. A., et al., Myricetin is a novel natural  
430 inhibitor of neoplastic cell transformation and MEK1, *Carcinogenesis*, 2007, *28*,  
431 1918-1927.

432 [20] Kang, N. J., Lee, K. W., Lee, D. E., et al., Cocoa procyanidins suppress  
433 transformation by inhibiting mitogen-activated protein kinase kinase, *J. Biol. Chem.*  
434 2008, *283*, 20664-20673.

435 [21] Kawamura, T., Hayashi, M., Mukai, R., et al., An efficient method for  
436 c8-prenylation of flavonols and flavanones. *Synthesis*. 2012, *44*, 1308-1314.

437 [22] Uto, T., Fujii, M., Hou, D.-X., 6-(Methylsulfinyl)hexyl isothiocyanate suppresses  
438 inducible nitric oxide synthase expression through the inhibition of Janus kinase  
439 2-mediated JNK pathway in lipopolysaccharide-activated murine macrophages,  
440 *Biochem. Pharmacol.* 2005, *70*, 1211-1221.

441 [23] Uto, T., Fujii, M., Hou, D.-X., Inhibition of lipopolysaccharide-induced  
442 cyclooxygenase-2 transcription by 6-(methylsulfinyl) hexyl isothiocyanate, a  
443 chemopreventive compound from *Wasabia japonica* (Miq.) Matsumura, in mouse  
444 macrophages. *Biochem. Pharmacol.* 2005, *70*, 1772-1784.

445 [24] You, S., Nakanishi, E., Kuwata, H., et al., Inhibitory effects and molecular  
446 mechanisms of garlic organosulfur compounds on the production of inflammatory  
447 mediators. *Mol. Nutr. Food Res.* 2013, *57*, 2049-2060.

448 [25] Kim, J. K. and Jun, J. G. Ailanthoidol suppresses lipopolysaccharide-stimulated  
449 inflammatory reactions in RAW264.7 cells and endotoxin shock in mice. *J. Cell.*  
450 *Biochem.* 2011, *112*, 3816-3823.

451 [26] Kumamoto, T., Fujii, M., Hou, D. -X., Akt is a direct target for myricetin to  
452 inhibit cell transformation. *Mol. Cell Biochem.* 2009, 332, 33-41.

453 [27] Xing, J., Li, R., Li, N., et al., Anti-inflammatory effect of procyanidin B1 on  
454 LPS-treated THP1 cells via interaction with the TLR4–MD-2 heterodimer and p38  
455 MAPK and NF-κB signaling. *Mol. Cell Biochem.* 2015, 407, 89-95.

456 [28] Park, B. S., Song, D. H., Kim, H, M., et al., The structural basis of  
457 lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature*, 2009, 458,  
458 1191-1196.

459 [29] Kim, J. E., Kwon, J. Y., Seo, S. K., et al, Cyanidin suppresses ultraviolet  
460 B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and  
461 Raf-1. *Biochem. Pharmacol.* 2010, 79, 1473-1482.

462 [30] Goto , J., Kataoka, R., Muta, H., et al., ASEDock docking based on alpha spheres  
463 and excluded volumes. *J. Chem. Inf. Model.* 2008, 48, 583-590.

464 [31] Mukai, R., Fujikura, Y., Murota, K., et al., Prenylation enhances quercetin uptake  
465 and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed  
466 long-term. *J. Nutr.* 2013, 143, 1558-1564.

467 [32] Tammela, P., Laitinen, L., Galkin, A., et al., Permeability characteristics and  
468 membrane affinity of flavonoids and alkyl gallates in Caco-2 cells and in  
469 phospholipid vesicles. *Arch. Biochem. Biophys.* 2004, 425, 193-199.

470 [33] Akira, S., Takeda, K., and Kaisho, T., Toll-like receptors: critical proteins linking  
471 innate and acquired immunity. *Nat. Immunol.* 2001, 2, 675-680.

472

473

474

475

476 **Figure Legends:**

477

478 **Figure 1.** The chemical structures of 8-prenyl quercetin (PQ) and quercetin (Q)

479

480 **Figure 2.** Influence of PQ and Q on the inflammatory mediators. PQ (A) and Q (B)  
481 inhibited LPS-induced expression of iNOS and COX-2. RAW264.7 cells were treated  
482 with the indicated concentrations of each sample for 30 min, and then exposed to 40  
483 ng/ml LPS for 12 h. COX-2 and iNOS were detected by Western blotting as described  
484 in Section 2. PQ (C, E) and Q (D, F) also inhibited the productions of LPS-induced NO  
485 and PGE<sub>2</sub>. RAW264.7 cells were treated as the same as above. The amount of nitrite (C,  
486 D) and PGE<sub>2</sub> (E, F) in culture medium were measured as described in Section 2. Each  
487 value represents the mean  $\pm$  S.D. of triplicate cultures. Means with differently lettered  
488 superscripts differ significantly each other at the probability of  $p < 0.05$ .

489

490 **Figure 3.** Influence of PQ and Q on the productions of LPS-induced cytokines. The  
491 culture and treatment of RAW264.7 cells were performed as described in Figure 2. The  
492 amounts of cytokines in culture medium were measured by the multi-plex technology as  
493 described in Section 2. Each value represents the mean  $\pm$  S.D. of triplicate cultures.  
494 Means with asterisk superscripts differ significantly at the probability of  $p < 0.05$ .

495

496 **Figure 4.** Inhibition of PQ and Q on LPS-induced mouse paw edema. The mice were  
497 divided into four groups: control, LPS, LPS plus PQ or Q, PQ or Q only. Each group  
498 had three mice, respectively. PQ (1  $\mu$ M/kg) or Q (2  $\mu$ M/kg) was injected *i.p.* for 4 days,  
499 and LPS (1 mg/kg) was then injected *s.c.* at mouse paw. The paw thickness was  
500 measured using digital caliper before and every hour after LPS treatment until 3 h (A).

501 The change in paw edema thickness was shown in (B). Means with differently lettered  
502 superscripts differ significantly against control at the probability of  $p < 0.05$ . The  
503 change in level of serum IL-6 is shown in (C). The blood serums were obtained from  
504 the mice that were treated with or without LPS for 3 h by collection of heart blood. The  
505 serum IL-6 was measured as described in Section 2. Each value represents the mean  $\pm$   
506 S.D. of three mice. Means with asterisk superscripts differ significantly at the  
507 probability of  $p < 0.05$ .

508

509 **Figure 5.** (A) The models of PQ and Q docking to TLR4. Hydrogen bonds are indicated  
510 by green lines in lower figure. *Blue ribbon*: TLR4 (Chain A), *green ribbon*: MD2  
511 (Chain B), *orange*: PQ, *yellow*: Q, *red*: LPS (Color figure online). (B) The competitive  
512 binding assay for PQ to TLR4 with FITC-conjugated LPS. RAW264.7 cells ( $5 \times 10^5$   
513 cells/ml in serum-free medium) were treated with or without PQ (15  $\mu$ M) or cold-LPS  
514 (unlabeled-LPS) (100 ng/ml) for 30 min before exposure to FITC-LPS (10 ng/ml) for 30  
515 min. After washing, the fluorescence emitted was analyzed with flow cytometry as  
516 described in Section 2.

517


518 **Figure 6.** Suppression of PQ and Q on the phosphorylation of SEK1, JNK1/2, MEK1  
519 and ERK1/2. RAW264.7 cells were pretreated with the indicated concentrations of PQ  
520 or Q for 30 min, and then exposed to 40 ng/ml LPS for 30 min. The phosphorylated  
521 protein kinases and  $\alpha$ -tubulin were detected with their antibodies, respectively. The  
522 induction fold of the phosphorylated kinase was calculated as the intensity of the  
523 treatment relative to that of control normalized to  $\alpha$ -tubulin by densitometry. The blots  
524 shown are the examples of three separate experiments.

525


526 **Figure 7.** Binding abilities of PQ and Q to SEK1 and JNK1/2 (A), MEK1 and ERK1/2  
527 (B). Whole cell lysate (input control, *lane 1*), lysate precipitation with Sepharose 4B  
528 beads (negative control, *lane 2*), Sepharose 4B-PQ-coupled beads (*lane 3*), and  
529 Sepharose 4B-Q-coupled beads (*lane 4*) were applied to SDS-PAGE and then detected  
530 with SEK1, JNK1/2, MEK1 or ERK1/2 antibody, respectively. The binding efficiency  
531 of each protein kinase to PQ or Q was presented as the ratio of input control,  
532 respectively.

533

534 **Figure 8.** The models of PQ and Q docking to MKK4 (SEK1) (A), JNK1 (B), MEK1  
535 (C), and ERK2 (D). Electrostatic potential surface is indicated in close-up figure of  
536 upper side, and hydrogen bonds are indicated by blue and green lines in lower figure.  
537 *Blue ribbon:* protein kinase, *red ribbon:* ATP-binding site, *orange:* PQ, *yellow:* Q (Color  
538 figure online).


**A**

8-prenyl quercetin (PQ)

**B**

Quercetin (Q)

**Fig.1 Hisanaga et al.**



**Fig.2 Hisanaga et al.**










Fig.3 Hisanaga et al.



**Fig.4 Hisanaga et al.**

A



B








Fig.5 Hisanaga et al.





**Fig. 6 Hisanaga et al.**

**A**

<b>PQ - Sepharose 4B</b>	-	-	+	-
<b>Q - Sepharose 4B</b>	-	-	-	+
<b>Sepharose 4B</b>	-	+	-	-
<b>Cell lysate</b>	+	+	+	+

**B**

<b>PQ - Sepharose 4B</b>	-	-	+	-
<b>Q - Sepharose 4B</b>	-	-	-	+
<b>Sepharose 4B</b>	-	+	-	-
<b>Cell lysate</b>	+	+	+	+



A







Fig.8 (A) Hisanaga et al.

**B****Fig.8 (B)** Hisanaga et al.

C





Fig.8 (C) Hisanaga et al.



**D****Fig.8 (D)** Hisanaga et al.